The GSK-3 family as therapeutic target for myocardial diseases
about
Adrenal G protein-coupled receptor kinase-2 in regulation of sympathetic nervous system activity in heart failureEnhanced Electrical Integration of Engineered Human Myocardium via Intramyocardial versus Epicardial Delivery in Infarcted Rat HeartsNatural product derivative BIO promotes recovery after myocardial infarction via unique modulation of the cardiac microenvironmentAblation of periostin inhibits post-infarction myocardial regeneration in neonatal mice mediated by the phosphatidylinositol 3 kinase/glycogen synthase kinase 3β/cyclin D1 signalling pathway.Live cell screening platform identifies PPARδ as a regulator of cardiomyocyte proliferation and cardiac repairElectrical and mechanical stimulation of cardiac cells and tissue constructs.Glycogen synthase kinase-3: a potential preventive target for prostate cancer managementChloroquine increases phosphorylation of AMPK and Akt in myotubes.Central role for GSK3β in the pathogenesis of arrhythmogenic cardiomyopathy.Aging and Autophagy in the HeartNutrient-sensing mTORC1: Integration of metabolic and autophagic signalsNovel Non-phosphorylated Serine 9/21 GSK3β/α Antibodies: Expanding the Tools for Studying GSK3 RegulationMicroRNA and receptor mediated signaling pathways as potential therapeutic targets in heart failure.How cardiomyocytes sense pathophysiological stresses for cardiac remodeling.Myocardial stress and autophagy: mechanisms and potential therapies.High-Content Assessment of Cardiac Function Using Heart-on-a-Chip Devices as Drug Screening Model.Coupling of myocardial stress resistance and signalling to voluntary activity and inactivity.Loss of Adult Cardiac Myocyte GSK-3 Leads to Mitotic Catastrophe Resulting in Fatal Dilated Cardiomyopathy.Chamber-specific differences in human cardiac fibroblast proliferation and responsiveness toward simvastatin.Response by Zhou et al to Letter Regarding Article, "Loss of Adult Cardiac Myocyte GSK-3 Leads to Mitotic Catastrophe Resulting in Fatal Dilated Cardiomyopathy".Atorvastatin protects cardiomyocytes against OGD/R‑induced apoptosis by inhibiting miR‑199a‑5p.Genomic analysis of an infant with intractable diarrhea and dilated cardiomyopathy.Ameliorative effect of nicotine exposure on insulin resistance is accompanied by decreased cardiac glycogen synthase kinase-3 and plasminogen activator inhibitor-1 during oral oestrogen-progestin therapy.GSK-3β heterozygous knockout is cardioprotective in a knockin mouse model of familial dilated cardiomyopathy.Angiogenesis in a 3D model containing adipose tissue stem cells and endothelial cells is mediated by canonical Wnt signaling.2,5-Dimethylcelecoxib prevents pressure-induced left ventricular remodeling through GSK-3 activation.A partnership with the proteasome; the destructive nature of GSK3.The allosteric glycogen synthase kinase-3 inhibitor NP12 limits myocardial remodeling and promotes angiogenesis in an acute myocardial infarction model.Cardiomyocyte-specific deletion of GSK-3β leads to cardiac dysfunction in a diet induced obesity model.Protein S-Nitrosylation Controls Glycogen Synthase Kinase 3β Function Independent of its Phosphorylation State.Glycogen synthase kinase 3β inhibition reduces mitochondrial oxidative stress in chronic myocardial ischemia.Wnt Signaling in Cardiac Remodeling and Heart Failure.The Impact of Chronic Glycogen Synthase Kinase-3 Inhibition on Remodeling of Normal and Pre-Diabetic Rat Hearts.Hydrostatic pressure suppresses fibrotic changes via Akt/GSK-3 signaling in human cardiac fibroblasts.Entanglement of GSK-3β, β-catenin and TGF-β1 signaling network to regulate myocardial fibrosis.Bi-directional genetic modulation of GSK-3β exacerbates hippocampal neuropathology in experimental status epilepticus
P2860
Q26785936-3D173A67-925B-46EE-B23D-3ADD5F850B16Q27303626-E5568FBD-BA76-407E-8342-9663AF37AA2BQ28597992-B01E24E2-FE60-486A-8C9B-AEA58C6AFB28Q30847428-3B4C8B83-4258-4242-909E-9C0896B951A2Q36407101-084097D8-6547-4928-8C3F-E19D34713F9EQ36421781-48011E42-C13B-410A-9EBF-14BE19041CB6Q36580561-572AD808-62E2-4C22-8D66-B93D0B48F8C2Q36754793-52CF36F9-3E8C-40C5-8B68-AD441A5AD0C3Q36884231-06319700-8CB3-4A79-B1C9-30A945E44D24Q36909023-A7CC7BCB-4873-4388-A30C-404EDA7D0C1FQ37008888-5C2C77B5-B695-44EC-90AE-5B6DFE40D9B3Q37418678-3DC82AF5-31F3-48CF-9A50-A73CDA35C6EDQ38842507-BCE6A802-6470-44A1-89FE-901ADC220226Q38974621-FF1140C7-B0E0-4EF6-94D9-987A65D2813EQ39210684-0DDBBCC9-7250-4E2F-A5FA-0EAD05A71E74Q39253982-CCABA9CD-8A14-4F09-A526-B41CA47E5A9DQ39770064-F45A4345-424F-42CC-AD43-67512BCC88D4Q40579189-BF2425B7-EDEA-4920-980B-04C0026A3758Q42361266-ABC4D747-B30C-4EBA-B1C4-B78BE7DBC083Q42365373-EE401B56-1424-4EBE-A996-9615C9B9C602Q42679599-04E95AEF-9EA8-4855-AA33-037797D98939Q45063174-AEF4A28F-FC81-4FCF-9DB2-51526892141DQ46442151-D763EA9A-AF3B-4866-81B0-D230296188D1Q46789847-60AA90AE-C7EB-4015-9805-8AFA461192ABQ47261919-88762EB6-A4D2-430D-910D-37674D89B879Q47388691-3EB3FCCB-9A08-4C89-A947-5C26EB9696A0Q47441648-BF101029-58A3-4040-8AF8-E89F7DC7F509Q47598692-C9B95E7B-8961-44A8-9628-6F742A4148FAQ49344334-0021A6F6-7EBE-4BBB-9131-3B9D67CEB73EQ52644178-71D9760A-31B9-46C0-A2F6-BA2051D993B9Q52727553-8B5CF7BF-EE09-4B98-BBE8-2720501A608EQ52815224-26DB456D-DE67-469C-8263-D9C7562EED0AQ52869439-21D96259-22AC-448E-B441-5594D3DB5CF8Q54112704-891B2C81-1AF6-4352-BED2-E03E235EC3C6Q54990315-99B9E0E4-2835-4963-8085-480CEF55018CQ58712518-32B3CE65-3AC0-4FD1-BBAC-0B679E30B441
P2860
The GSK-3 family as therapeutic target for myocardial diseases
description
2015 nî lūn-bûn
@nan
2015 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2015 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
name
The GSK-3 family as therapeutic target for myocardial diseases
@ast
The GSK-3 family as therapeutic target for myocardial diseases
@en
The GSK-3 family as therapeutic target for myocardial diseases
@nl
type
label
The GSK-3 family as therapeutic target for myocardial diseases
@ast
The GSK-3 family as therapeutic target for myocardial diseases
@en
The GSK-3 family as therapeutic target for myocardial diseases
@nl
prefLabel
The GSK-3 family as therapeutic target for myocardial diseases
@ast
The GSK-3 family as therapeutic target for myocardial diseases
@en
The GSK-3 family as therapeutic target for myocardial diseases
@nl
P2860
P50
P3181
P1433
P1476
The GSK-3 family as therapeutic target for myocardial diseases
@en
P2860
P304
P3181
P356
10.1161/CIRCRESAHA.116.303613
P407
P577
2015-01-02T00:00:00Z